Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Peripheral 1Liposarcoma 1Inhibition of Autophagy Synergizes Anti-tumor Effect 1Immunoblastic Lymphadenopathy 1Gastro-enteropancreatic neuroendocrine tumor 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

Vincristine 5Doxorubicin 5Cyclophosphamide 5Prednisone 4Peripheral Blood Stem Cell Transplantation 4Rituximab 3Ifosfamide 3Everolimus 3Etoposide 3Carboplatin 3romidepsin 2pembrolizumab 2fludarabine phosphate 2Whole-Body Irradiation 2Vorinostat 2Mycophenolic Acid 2Microarray Analysis 2Lenalidomide 2Immunohistochemistry 2Gene Expression Profiling 2Cyclosporine 2Clofarabine 210-propargyl-10-deazaaminopterin 2veliparib 1prednylidene 1liposomal doxorubicin 1indolepropanol phosphate 1flt3 ligand protein 1etoposide phosphate 1ethanolamine oleate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoblastic Lymphadenopathy × Clinical Trials, Phase II as Topic × Clear all
NCT02223208 2025-12-02

FIL_PTCL13

Fondazione Italiana Linfomi - ETS

Phase 1/2 Active not recruiting
89 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡